Last updated: July 14, 2026
INTELENCE (etravirine) is an antiretroviral reverse transcriptase inhibitor (NNRTI) within HIV therapy portfolios. From an investment-patent perspective, the asset’s risk profile is dominated by (1) long-past core patent/exclusivity expirations in the US and (2) a mature global generic market, which compresses forward pricing power and shifts valuation sensitivity toward brand life-cycle management, contract access, and relative supply strength rather than IP-driven margin expansion.
What patents protect INTELENCE (etravirine) and how strong is the patent estate?
Direct answer: INTELENCE’s patent protection has largely moved into post-expiration territory for active-ingredient protection; the remaining investable value has historically come from formulation/process, dosing regimen, and potentially incremental-use claims, depending on jurisdiction and filing strategy. The core practical conclusion for investors: etravirine is not positioned as an “IP-led” long-dated payer/coverage story in 2026.
Core patent estate: what typically persisted after launch
For legacy small-molecule HIV drugs like etravirine, the last value pockets usually cluster into:
- Polymorph/crystal form claims tied to drug substance or solid state behavior.
- Formulation claims (tablet composition, excipients, particle size or stabilizers).
- Manufacturing process claims (granulation, compression, drying conditions).
- Method-of-use claims (specific regimens, lines of therapy, or combination rule sets).
Jurisdictional reality for investors
Because HIV small molecules launched earlier than the current reimbursement cycle expectations, the US and most major markets generally reached generic entry decades ago, meaning the relevant question for valuation is not “how many patents left?” but “whether any enforceable barriers remain and whether they still matter commercially.”
When does INTELENCE lose exclusivity or expire patents by market?
Direct answer: The commercial exclusivity window for etravirine ended long ago; the remaining effect is usually limited to residual formulation/process claims in specific countries, not to preventing generic supply on the active ingredient. As of 2026, exclusivity timing is not the binding constraint on supply competition.
US exclusivity and practical impact
- Small-molecule exclusivity is typically front-loaded via new chemical entity protections and/or later-manufacturing/formulation exclusivities tied to specific NDA supplement submissions.
- Post-exclusivity, generic entry becomes the primary driver of pricing dynamics, with ongoing brand survival dependent on contracting, tender placement, and patient/physician switching friction.
EU and UK
- EU market exclusivity and supplementary protection (SPCs) historically depended on patent coverage and regulatory data exclusivity categories.
- For mature small molecules, the binding constraint is the availability of bioequivalent generics and substitution under payer formularies.
What is the Orange Book status of INTELENCE (etravirine) in the US?
Direct answer: INTELENCE’s Orange Book-related practical posture is a mature generic landscape rather than a “no-generic” status. The investment takeaway is that the relevant Orange Book signal for etravirine is mostly about existing listed patents and whether any are still within enforceable terms.
What to extract from the Orange Book for an investment model
Investors typically model:
- Listed patent numbers (drug substance and formulation).
- Patent expiration dates.
- Whether patents have been “carved out” or are tied to specific strengths/dosage forms.
- Pending or completed Paragraph IV litigation markers.
What generic entry risks exist for INTELENCE (etravirine)?
Direct answer: The key generic entry risk is mostly historical. For current investment horizons, the dominant risks are:
- Competitive intensity from settled generic supply chains.
- Contracting-driven share loss rather than “first generic win.”
- Supply disruptions in the generic tier that can temporarily reprice products upward.
Paragraph IV risk is generally not the driver now
Paragraph IV (ANDA) challenges matter when a brand is still within a live exclusivity window. For etravirine, the more relevant investor view is pricing and distribution structure rather than the timing of new Paragraph IV filings.
How many patents cover etravirine tablets and what formulations are protected?
Direct answer: For a legacy NNRTI like etravirine, formulation patent coverage tends to concentrate on:
- Specific tablet compositions and excipient systems.
- Solid state properties and manufacturing parameters.
- Potential stability and bioavailability-related parameters.
Dosage form granularity that affects enforceability
In practice, enforceability and generic freedom-to-operate can differ by:
- Strength (each tablet strength can have distinct labeling and sometimes distinct listed patents).
- Manufacturing method (process claims can be strong even when composition claims are weak).
- Specific excipient substitutions (if a generic is non-infringing by composition, it may still face process enforcement risk).
What patent litigation affects INTELENCE (etravirine) and who has challenged it?
Direct answer: For legacy small molecules, litigation history tends to be concentrated around earlier generic entry periods. Current investment impact is less about active suits and more about whether settlements created practical launch timing locks and whether exclusivity already expired.
Settlement-driven effects investors should model
Even when active litigation is over, settlements can cause:
- “Design-around” commitments that shape market product characteristics.
- Earlier/later launch for specific generic filers.
- Ongoing brand/generic co-existence patterns by wholesaler.
What FDA regulatory status does INTELENCE (etravirine) have and what matters for investors?
Direct answer: INTELENCE is an FDA-approved HIV therapy product. For investors, the ongoing regulatory relevance is typically not initial approval but:
- Changes to labeling, safety communications, and contraindications.
- Manufacturing site changes and facility compliance history (affecting supply and contract reliability).
- Generic interchangeability pressure under pharmacy benefit manager (PBM) rules.
Label and lifecycle considerations that move economics
- HIV regimen preferences can shift with newer ART classes (integrase inhibitors, newer NNRTIs), which changes demand mix independent of IP.
- Safety/tolerability events can affect adherence and switching, even without IP triggers.
How does INTELENCE compare with other NNRTIs and HIV ART in terms of competitive position?
Direct answer: In HIV NNRTI space, the competitive baseline has shifted materially toward newer agents and combination protocols. Etravirine remains a treatment option, but portfolio demand often follows:
- Line-of-therapy placement (salvage/regimen construction).
- Resistance profile utility.
- Formulary positioning versus newer NNRTIs and integrase-based regimens.
Competitive pressure drivers investors model
- Formulary tiering (preferred vs non-preferred).
- Generic availability and PBM rebates on the substitutable products.
- Patient persistence and regimen switching due to tolerability.
What licensing deals, co-promotion structures, or supply agreements influence INTELENCE pricing and volume?
Direct answer: For mature generics-adjacent brands, economics are driven by:
- Pharmacy distribution and contract terms with major wholesalers and IDNs.
- PBM rebates and formulary access.
- Long-term supply agreements and manufacturing redundancy.
Why IP is not the only value driver now
Once active-ingredient exclusivity is gone, investor returns depend on:
- Supply stability and fill-rate performance.
- Distribution leverage and payer relationships.
- Brand retention programs where clinically justified.
What manufacturing/IP barriers could still protect INTELENCE from low-cost substitution?
Direct answer: If composition and process IP is largely expired, manufacturing barriers that can still matter are practical rather than legal:
- Yield, cost of goods (COGS), and supply chain reliability.
- Stability handling and warehousing constraints tied to tablet solid-state behavior.
- Quality system robustness to avoid FDA action that can remove supply from tender channels.
Commercial fundamentals: how should investors frame revenue exposure for INTELENCE?
Direct answer: Revenue exposure should be framed as a mature, price-sensitive product with share determined by contract access and substitution dynamics rather than IP exclusivity.
Revenue sensitivity factors
- Net price compression as generic competition expands and PBMs adjust preferred status.
- Volume stability driven by clinical necessity in specific resistance contexts.
- Risk of formulary delisting that forces switching to other NNRTIs or combination ART.
Investment conclusion for the fundamental model
- Upside is capped unless there is a renewed differentiating clinical/formulary use case or supply constraints.
- Downside risk is driven by continued generic substitution and contracting pressure.
Biosimilar risk: does INTELENCE face biologics-style competition?
Direct answer: No. INTELENCE is a small-molecule drug, so “biosimilar risk” is not applicable. Competitive risk is generic small-molecule ANDA competition and tender contracting, not biosimilar interchange.
Key Takeaways
- INTELENCE (etravirine) is a mature HIV NNRTI with investment value dominated by contracting, supply stability, and formulary positioning rather than active remaining IP exclusivity.
- The principal patent-driven “entry prevention” questions are largely historical; current valuation sensitivity shifts to pricing and share under generic substitution.
- The most actionable investor diligence is to map Orange Book listings to any still-live enforceable patents by jurisdiction and to assess whether litigation outcomes materially shaped market supply timing. In 2026, the broader commercial picture remains price-compressed and contract-driven.
FAQs
- What are the most important remaining patent categories for etravirine tablets (composition vs process vs method-of-use)?
- Do any settlements or consent decrees from earlier ANDA litigation still affect generic launch timing for etravirine?
- How do PBM formularies typically treat older NNRTIs like etravirine versus newer ART classes in salvage regimens?
- What FDA manufacturing compliance issues most commonly disrupt supply for legacy solid oral products like INTELENCE?
- What factors drive net price versus gross price for mature HIV therapies under wholesaler and hospital contracting?
References
No cited sources are provided because no source set (e.g., FDA Orange Book listing, patent database extracts, or litigation docket records) was included in the prompt.
